ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Nigella sativa oil

Also written as “NP101”, “NP-101” and “NP101 Sumatriptan Iontophoretic Transdermal Patch”.

Its studies are mostly in Migraine Disorders · Gastro-enteropancreatic neuroendocrine tumor · COVID-19, led by 2 companies.

Drug pageNigella sativa oil: every studyAll 25 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Nov 14, 20087 company-led studies, 1 open or runningNext primary completion: Dec 2029 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Teva Pharmaceutical Industriesits history only50 open or runningphase 3since Nov 14, 2008Jul 21, 2008none ahead
Novatek Pharmaceuticals21 open or runningphase 3since Oct 6, 2026Mar 23, 2023Dec 2029phase 3 · NCT07935928

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Novatek Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 23, 2023First study: phase 2 study in COVID-19First studyNCT05785390 · 170 enrolled · United States
  2. Oct 6, 2026Phase 3 study in Gastroenteropancreatic Neuroendocrine TumorsPhase 3 reachedNCT07935928 · 381 planned

Ahead

  1. Dec 2029Primary completion: phase 3 study in Gastroenteropancreatic Neuroendocrine TumorsNCT07935928

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 Novatek Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07935928Gastroenteropancreatic Neuroendocrine Tumors3Not yet recruitingDec 2029381
NCT05785390COVID-19 · United States2TerminatedMay 9, 2025170

How it is read

Names in the registry

  • “NP101”, 3 entries
  • “NP-101”, 2 entries
  • “NP101 Sumatriptan Iontophoretic Transdermal Patch”, 1 entry
  • “NP101 Study Patch”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.